All articles by Globaldata Healthcare

Globaldata Healthcare

Schizophrenia market expected to reach $17bn across 7MM by 2031

The schizophrenia market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the US) is…
HPV vaccine reduces cervical cancer risk by 87%, but uptake remains poor

The first study to effectively demonstrate the impact of human papillomavirus (HPV) vaccination on cervical cancer incidence has been recently…
Breast cancer awareness month: Remembering the burden of this disease

According to the World Health Organization (WHO), breast cancer is the second most common cancer in the world and the…
US leads actively recruiting clinical trials for Covid-19

As new strains of COVID-19 continue to drive new cases globally, companies and institutions have continued development of interventions for…
Potential FDA Approval on the Way for Amylyx’s AMX0035 in ALS Ahead of Time

Potential FDA Approval for Amylyx's AMX0035 for ALS On September 15, Amylyx Pharmaceuticals announced that its bid to submit a…

Resumed trials continue to increase further

Since early March 2020, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due…
Seelos Therapeutics’ intranasal ketamine offers promise in treating suicidality

On July 6, Seelos Therapeutics announced that the first patient has been dosed in the second part of their registrational,…
ASCO 2021: LAG-3 is now a validated target in Melanoma

At the virtual 2021 annual American Society of Clinical Oncology conference (ASCO 2021) on June 4–8, results from the Phase…
ASCO 2021: Compelling data For Ciltacabtagene Autoleucel in multiple myeloma

At the virtual 2021 annual American Society of Clinical Oncology conference (ASCO 2021) on June 4–8, Johnson & Johnson (J&J)…
Microbiome therapeutics rising as potential immuno-oncology agents

Clinical data and industry partnerships have fueled a shift in perception of the microbiome-based therapeutic market from nascent to developing,…